Anthony Martinez, Ph.D.
Postdoctoral Fellow
Personal Statement:
Under the mentorship of Dr. David Maguire, Anthony’s research seeks to characterize the effects of opioid/non-opioid mixtures on drug discrimination, ventilation, dependence, and withdrawal. His studies utilize highly translational animal models to gain a better understanding of the behavioral pharmacology of opioids/non-opioid mixtures that will ultimately help to find safe and effective treatments.
Education
PhD in Pharmacology
University of Texas Health Science Center at San Antonio
San Antonio, TX
BS in Biochemistry
Angelo State University
San Angelo, TX
Research
|
• Behavioral pharmacology |
|
• Preclinical models |
- Animal behavior
Awards & Accomplishments
NIDA T32 Training Program Postdoctoral Training in Drug Abuse Research: Behavior & Neurobiology (2024-present)
Publications
Martinez PA, Martinez VE, Rani CSS, Murrell, M, Javors M, Gelfond, J, Doorn, JA, Fernandez E, Strong R (2023) Impaired aldehyde detoxification exacerbates motor deficits in an alpha-synuclein mouse model of Parkinson’s disease. Brain and Behavior 13(9):e3150. doi: 10.1002/brb3.3150. Epub 2023 Jul 14.
Masato A, Plotegher N, Terrin F, Sandre M, Faustini G, Thor A, Adams S, Berti G, Cogo S, De Lazzari F, Fontana CM, Martinez PA, Strong R, Bandopadhyay R, Bisaglia M, Bellucci A, Greggio E, Valle LD, Boassa D, Bubacco L (2023) DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease. NPJ Parkinsons Disease 9(1):42. doi: 10.1038/s41531-023-00485-1
Strong R, Miller RA, Bogue M, Fernandez E, Javors MA, Libert S, Martinez PA, Murphy MP, Musi, N, Nelson JF, Petrascheck M, Reifsnyder M, Richardson A, Salmon AB, Macchiarini F, Harrison DE (2020) Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects. Aging Cell doi.org/10.1111/acel.13269
Song C, Zhang J, Qi S, Liu Z, Zhang X, Zheng Y, Andersen JP, Zhang W, Strong R, Martinez PA, Musi N, Nie J, Shi Y (2019) Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s disease. Aging Cell e12941. Doi:10.1111/acel.12941
Bai X, Wey MC, Martinez PA, Shi C, Fernandez E, Strong R (2017) Neurochemical and motor changes in mice with combined mutations linked to Parkinson’s disease. Pathobiology of Aging & Age-related Diseases 7(1)1267855. doi: 10.1080/20010001.2017.1267855
Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, Pedro de Magalhaes J, Martinez PA, McCord JM, Miller BF, Muller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE (2016) Longer lifespan in male mice treated with a weakly-estrogenic agonist, an antioxidant, an a-glucosidase inhibitor or a Nrf2-inducer. Aging Cell doi:10.111/acel12496
Xiuhua L, Redus L, Chen C, Martinez PA, Strong R, Li S, O’Connor JC (2013) Cognitive dysfunction precedes the onset of motor symptoms in the Mitopark mouse model of Parkinson’s disease. PLoS One 8(8):e71341. doi:101371/journal.pone.0071341
Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: Implications for Parkinson’s Disease. PLoS One 7(2):e31522. doi:10.1371/journal.pone.0031522
Green MK, Rani SS, Joshi A, Soto-Pina AE, Martinez PA, Frazer A, Strong R, Morilak DA (2011) Prenatal stress induces long term stress vulnerability, compromising stress response systems in the brain and impairing extinction of conditioned fear after adult stress. Neuroscience 192:438-451.
Manuscripts in preparation
Singh R, Calderon VE, Halloran J, Holstein D, Diaz V, Gelfond J, Martinez PA, Galvan V, Javors M, Fernandez E, Lechleiter J, Strong R. Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice. 2024. To be submitted to The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.